skip to main content

    Updated Visitor Guidelines

 

MENU

 

Rogel Cancer Center Members Attend 2024 ASCO Annual Meeting

Check out the list of U-M presenters to support your colleagues. Connect with researchers on X/Twitter using #AACR24. Be sure to tag @UMRogelCancer.

Meet the Team

The University of Michigan Rogel Cancer Center is built on a foundation of comprehensive, integrated and interdisciplinary specialty care. Although a patient may not see each member of the team, all of the specialists listed below are involved in reviewing patients’ cases and recommending a treatment plan that is coordinated and tailored to the individual patient.

Pancreatic Neuroendocrine Tumors

Pancreatic neuroendocrine tumors (NETs) arise from neuroendocrine cells (also called islet cells) that are present in the pancreas organ and responsible for secretion of many chemicals and hormones responsible for control of that organ as well as other distant organs.

These pancreatic NETs or islet cell tumors are rare and occur in only about 2 of every 100,000 people. The pancreatic NETs account for less than 5% of all pancreatic cancers. The management of pancreatic NETs depends on the following:

Gastrointestinal Neuroendocrine Tumors

Gastrointestinal (GI) neuroendocrine tumors (NETs) arise from neuroendocrine cells that are present in our GI organs and responsible for secretion of many chemicals and hormones responsible for control of that organ as well as other distant organs.

These tumors are rare and occur in only about 2 of every 100,000 people. The management of GI-NETs depends on the following:

Haymart gets $3.3M to develop risk-based approach to thyroid cancer survivorship care

Do all thyroid cancer survivors need the same level of follow-up care and monitoring? With a new $3.3 million grant from the National Cancer Institute, Megan Haymart, M.D., will identify survivors at different risks of recurrence and develop a system for long-term monitoring based on that risk.

With $5M grant, Rogel team will conduct preclinical work to develop drugs targeting cancer master regulator

University of Michigan Rogel Cancer Center researcher Arul Chinnaiyan, M.D., Ph.D., has received a $5 million grant from the J.C. Kennedy Foundation to conduct laboratory tests of a potential drug candidate targeting a master regulator that controls the majority of genes involved in the most challenging type of prostate cancer.

Pages